ArticlePediatric cardiology2026
Exploring Serum Biomarker Levels in Tetralogy of Fallot, Hypoplastic Left Heart Syndrome, and Healthy Children.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evolving Proteomic Biomarkers in Children with Congenital Heart Defects.Journal of cardiovascular development and disease · 2026Review
- NT-proBNP and hs-CRP may be useful biomarkers for identifying and stratifying repaired TOF patients at increased risk of RV systolic dysfunction.Journal of family medicine and primary care · 2026Article
- Risk factors and a predictive model for delayed extubation in children undergoing primary repair of tetralogy of Fallot: a retrospective cohort study with rigorous methodological validation.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum biomarkers have emerged as tools for diagnosis and management in adult heart disease but are less investigated in the pediatric population. This exploratory study reports biomarker profiles in unrepaired tetralogy of Fallot (TOF), repaired TOF (rTOF), hypoplastic left heart syndrome (HLHS) following Fontan surgery, and healthy controls. We compared circulating biomarker patterns between TOF, rTOF, HLHS, and control groups, aiming to characterize potential disease-specific profiles and generate hypotheses for future research. We prospectively enrolled subjects and collected single-time blood samples for analysis. We measured: microRNA-21 (miR-21), soluble suppression of tumorigenicity-2 (sST-2), galectin-3 (Gal-3), procollagen type-I carboxy-terminal pro-peptide (PICP), procollagen type-III amino-terminal pro-peptide (PIIINP), metalloproteinases (MMP-1/MMP-9), and NT-proBNP. We included 207 patients: TOF (n = 75), rTOF (n = 60), HLHS (n = 11), and healthy controls (n = 60). Compared to the younger controls, TOF patients had higher PICP, MMP-1, and NT-proBNP. Compared to older controls, rTOF patients had higher PIIINP, MMP-1, MMP-9, and NT-proBNP; and HLHS patients had higher PIIINP and MMP-1. Collagen metabolism biomarkers and MMP-1 were elevated across disease groups. Gal-3 was associated with age in HLHS. No disease-specific patterns were observed; however, differences from controls suggest cardiac remodeling in TOF and HLHS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.